Dick is Co-Founder of NEA and and previously Chairman of the NEA Management Company. He was Managing General Partner of the firm through NEA VII when he turned the reins over to Peter Barris and became a General Partner. During the 20 years Dick was the Managing General Partner of NEA, the partnership achieved top quartile returns for its Limited Partners. Dick began his venture career in 1969 as a General Partner with Arthur Rock and Co. after nine years in general management as Manager of Financial Planning at the Kroger Co. and in investment management as Executive Vice President at Gardner & Preston Moss Company in Boston. In 1977 Dick was an early investor in Apple Computer for his own account. Since co-founding NEA in 1978, he has been involved in ten companies that have grown from start-up or near start-up stage to companies with market value in excess of $1 billion

Chuck has been at the forefront of innovation in healthcare since co-founding NEA in 1977, with a focus on healthcare services, healthcare information technology and biopharmaceutical investments. His long track record of successful investing includes numerous companies that achieved market capitalizations in excess of $1 billion, and through those investments Chuck has played an integral role in transforming the health care delivery system. He has served as a director of more than 50 venture-backed companies, and currently serves on the boards of Interfusio, Neuropace, Supernus Pharmaceuticals, and Vitae Pharmaceuticals. His prior board memberships include AMERIGROUP, Bravo Health, Caremark, Chomerics, CoGenesys, Comp Health, Genetic Therapy, LifeMetrix, Life Technologies, PatientKeeper, Russ Pharmaceuticals, Senseonics, Scandipharm, Sepracor, Surgical Health, and Zymark Corporation.

In founding NEA, Chuck and his co-founders wanted to build a ‘100-year-firm’—a unique perspective that ultimately enabled NEA to transition, transform and scale as venture capital evolved. Chuck's role in shaping and institutionalizing NEA's collaborative, entrepreneur-focused culture is a key factor in the firm's continued success. In addition to that legacy, Chuck played an integral role in the broader industry's maturation, not only as an investor but as a thought leader and advocate. He founded the Mid-Atlantic Venture Capital Association (MAVA), which now has over 80 venture capital firms that are members, and is one of the most active regional venture associations in the country. He is Chairman Emeritus of MAVA. Chuck continues to be deeply engaged as a venture capital industry advocate and is frequently invited to speak to organizations and institutions about the state of the industry. Recently he worked with Peter Bancroft, a well-known former venture capitalist, the NVCA, and Harvard University to record the oral histories of leading VCs so that the histories of the firms will not be lost. Sixty interviews have been conducted or scheduled so far. He is a Trustee of the Baltimore Museum of Art and a Member of the University of Maryland, Baltimore County Board of Visitors.

Before co-founding NEA, Chuck was Vice President of T. Rowe Price Associates (Vice President of their New Horizons Fund). He served in Vietnam, commanding an independent platoon including an initial reconnaissance of Hamburger Hill. His decorations include the Silver Star and Bronze Star V (1st OLC.). He received his MBA from the Harvard University Graduate School of Business and his BA in English Literature with honors from the University of Pennsylvania.

Since retiring from his General Partner role at NEA in 2003, Frank has remained an active angel investor as Founder and Managing Partner of Bonsal Capital, LLC, as Special Partner of New Markets Venture Partners, and as advisor to and Limited Partner in numerous funds in North America, the United Kingdom, and Europe, including Amadeus Capital Partners (UK), Boulder Ventures (MD/CO), Novak Biddle Venture Partners (MD), Sterling Ventures (MD), Trellis Partners (TX), Venturehouse (DC), and Windward Ventures (CA).

Jim joined NEA in 2001, he is a retired General Partner who specialized in biotechnology and worked with members of NEA's healthcare investment group on medical devices and specialty pharmaceutical companies. Previous board memberships include Amicus Therapeutics, Cardioxyl Pharmaceuticals, Cerecor Inc., Clovis Oncology, GlycoMimetics, Inc., PhaseBio Pharmaceuticals, Psyadon Pharmaceuticals, Roka Bioscience, Senseonics, Supernus Pharmaceuticals, Inc., Targacept, Inc. (NASDAQ: TRGT) and Zosano Pharma, Inc. Jim formerly served on the boards of exited companies: CoGenesys (acquired by Teva Pharmaceutical Industries), Iomai Corporation (acquired by Intercell AG), MedImmune, Inc. (acquired by AstraZeneca), Pharmion (acquired by Celgene), Inhibitex, Inc. (NASDAQ: INHX, acquired by Bristol-Myers Squibb), and Peptimmune, Inc. Prior to NEA, Jim served as Founder, Chairman and CEO of Sensors for Medicine and Science (1997 - 2001). Prior to that, he led three NEA-funded companies, serving as Chairman and CEO of Genetic Therapy, Inc. (1987 - 1995), President and CEO of Life Technologies (1985 - 1987), and President and CEO of Bethesda Research Labs (1982 - 1983). Prior to 1982, Jim worked in various divisions of SmithKline. Jim received a PhD in Biochemistry at the University of Tennessee, his MBA from the University of Santa Clara, and a BS in Chemistry from Boston College.